The results showed that atelizumab combined with antiangiogenic therapy and chemotherapy provided significant PFS benefits in advanced NSCLC patients with EGFR or ALK mutations, low Teff expression, PD-L1 negativity, and liver metastasis compared with the control group (anti-angiogenesis combined chemotherapy), providing evidence of the effectiveness of the combination therapy, and the safety risks were consistent with previously reported single-agent therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.